Brainstorm Cell Therapeutics INC 8-K filings

Brainstorm Cell Therapeutics announces leadership transitions, appointing Peter Pitts as Executive Chairman and Jacob Frenkel as Senior Advisor.

BrainStorm Cell Therapeutics has appointed former FDA Associate Commissioner Peter J. Pitts to its Board of Directors as it prepares for a Phase 3b ALS trial.

BrainStorm Cell Therapeutics reports Q1 2026 financial results while advancing preparations for its Phase 3b ENDURANCE ALS trial.

BrainStorm Cell Therapeutics announced its full year 2025 financial results, reporting a reduced net loss and highlighting progress on its NurOwn Phase 3b study for ALS, supported by a recent $2 million financing.

Brainstorm Cell Therapeutics Inc. announced a $1 million private placement and an increase in its stock incentive plan pool.

Brainstorm Cell Therapeutics Inc. has entered into a $1 million private placement agreement to sell common stock and warrants for working capital.

Brainstorm Cell Therapeutics Inc. entered into three separate agreements to issue convertible promissory notes totaling $329,175 in principal, securing approximately $279,000 in net proceeds after significant discounts and fees.

Brainstorm Cell Therapeutics announced Q3 2025 financial results and secured a $143,750 promissory note to fund operations and advance its NurOwn Phase 3b ALS trial.

Brainstorm Cell Therapeutics Inc. has entered into a securities purchase agreement for a $182,400 promissory note, receiving $155,000 in net proceeds for working capital.

BrainStorm Cell Therapeutics announced FDA clearance for its NurOwn Phase 3b ALS trial and reported second quarter 2025 financial results, including an increased net loss.

Brainstorm Cell Therapeutics Inc. announced its common stock will be delisted from the Nasdaq Capital Market due to non-compliance with minimum shareholder equity requirements and will transition to trading on the OTCQB Venture Market.

Brainstorm Cell Therapeutics Inc. announced that its stockholders approved the election of seven directors, ratified its independent auditor, and significantly expanded its equity incentive plan share pool at the Annual Meeting held on June 25, 2025.

BrainStorm Cell Therapeutics announced new survival data from its NurOwn Expanded Access Program for ALS, showing 90% of participants survived over five years from symptom onset, significantly exceeding typical ALS survival rates.

Brainstorm Cell Therapeutics has received FDA clearance to initiate a Phase 3b clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm Cell Therapeutics reported its Q1 2025 financial results, highlighting progress in its NurOwn development program and the planned Phase 3b clinical trial for ALS.

Brainstorm Cell Therapeutics reduces the quorum requirement for stockholder meetings and announces the date and deadlines for its 2025 Annual Meeting.

Brainstorm Cell Therapeutics reported its full year 2024 financial results, highlighting progress with its NurOwn ALS treatment and a warrant inducement agreement to raise $1.64 million.

Brainstorm Cell Therapeutics enters into an agreement with an institutional holder to exercise existing warrants, generating $1.64 million in gross proceeds for working capital and general corporate purposes.

Brainstorm Cell Therapeutics receives an extension from Nasdaq until June 30, 2025, to meet listing requirements, contingent on achieving a minimum stockholders' equity of $2.5 million and demonstrating progress in capital raising.

Brainstorm Cell Therapeutics has appealed Nasdaq's decision to delist its stock after failing to meet minimum market value requirements.

Brainstorm Cell Therapeutics received notice from Nasdaq regarding failure to meet minimum market value requirements, potentially leading to delisting of its common stock.

Brainstorm Cell Therapeutics reported its third quarter 2024 financial results and provided an update on the progress of its NurOwn program for ALS, including a planned Phase 3b trial.

Brainstorm Cell Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Brainstorm Cell Therapeutics enacted a 1-for-15 reverse stock split on September 30, 2024, to boost its share price and meet Nasdaq's minimum bid price requirement.

Brainstorm Cell Therapeutics is progressing its NurOwn cell therapy for ALS with a refined Phase 3b trial design, aiming for regulatory approval.

Brainstorm Cell Therapeutics has approved a 1-for-15 reverse stock split of its common stock, effective September 30, 2024.

Brainstorm Cell Therapeutics' shareholders approved an increase in authorized shares, amendments to stock incentive plans, and the election of board members at their annual meeting.

BrainStorm Cell Therapeutics reports alignment with the FDA on key aspects of its Phase 3b trial for NurOwn in ALS, alongside its second quarter 2024 financial results.

Brainstorm Cell Therapeutics has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

Brainstorm Cell Therapeutics has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting its listing status at risk.